Accuracy of spot sign in predicting hematoma expansion and clinical outcome
A meta-analysis

Xinghua Xu, MD\textsuperscript{a,b}, Jiashu Zhang, MD\textsuperscript{a,b}, Kai Yang, MM\textsuperscript{c}, Qun Wang, MD\textsuperscript{a}, Bainan Xu, MD\textsuperscript{a}, Xiaolei Chen, MD\textsuperscript{a,b,}\textsuperscript{\ast}

Abstract

Background: Spot sign on computed tomography angiography (CTA) has been reported as a risk factor for hematoma expansion (HE) and poor outcome after intracerebral hemorrhage (ICH). We performed a meta-analysis to investigate the predictive accuracy of spot sign for HE, mortality risk, and poor outcome.

Methods: We searched PubMed, Embase, and the Cochrane Library for relevant studies. Studies were incorporated if they reported data on relationship between CTA spot sign and HE, mortality or poor outcome.

Results: Twenty-nine studies were pooled in this meta-analysis. The spot sign occurred in 23.4\% patients with spontaneous ICH undergoing CTA scans. It showed a sensitivity of 62\% (95\% confidence interval [CI] 54–69), with a specificity of 88\% (95\% CI 85–91). Spot sign was related with increased risk of HE (odds ratios [OR] 8.49, 95\% CI 7.28–9.90). In the analysis of association between spot sign and outcome, patients with spot sign had a significant higher risk of in-hospital death (OR 5.08, 95\% CI 3.16–8.18) and 3-month death (OR 3.80, 95\% CI 2.62–5.62). The spot sign was also a predictor of poor outcome at discharge (OR 6.40, 95\% CI 3.41–12.03) and at 3 months (OR 4.44, 95\% CI 2.33–8.46).

Conclusions: The overall incidence of CTA spot sign in spontaneous ICH patients is substantial. Spot sign demonstrated a good diagnostic performance in predicting HE and was closely associated with increased risk of death and poor outcome.

Abbreviations: AUC = area under the curve, CI = confidence interval, CT = computed tomography, CTA = CT angiography, DOR = diagnostic odds ratio, HE = hematoma expansion, ICH = intracerebral hemorrhage, mRS = modified Rankin Scale, NLR = negative likelihood ratio, OR = odds ratio, PLR = positive likelihood ratio, SROC = summary receiver operating characteristic.

Keywords: clinical outcome, hematoma expansion, intracerebral hemorrhage, meta-analysis, spot sign

1. Introduction

Spontaneous intracerebral hemorrhage (ICH) is the most devastating type of stroke, with a mortality up to 40\% at 30 days after ictus and only one-fifth of the survivors could live independently after 6 months.\textsuperscript{[1]} Although most determinants of ICH outcome, such as hematoma location and baseline volume, are unmodifiable at presentation,\textsuperscript{[2]} clinically significant hematoma expansion (HE), occurring in up to a third of patients with ICH,\textsuperscript{[3]} has been identified as one of the most important determinants of early neurological deterioration and poor clinical outcomes in spontaneous ICH patients.\textsuperscript{[4,5]} Many ICHs still expand at the time of initial emergency department assessment, causing increased risk of death or disability. Therefore, HE is a promising potential treatment target to improve prognosis of ICH.\textsuperscript{[6,7]} Hemostatic therapy may be efficient in preventing HE for patients with ICH, but it carries the risk of thromboembolic events in inappropriate patients. A reliable approach to accurately predict HE and further clinical outcome is of key importance for choosing potentially best therapeutic strategy for ICH.

Recently, spot sign, well acknowledged as unifocal or multifocal contrast enhancement within an acute spontaneous ICH visible on computed tomography angiography (CTA) source images and discontinuous from adjacent normal or abnormal blood vessels, has been regarded as a potential predictor of HE and risk factor of death or poor outcome.\textsuperscript{[8]} So far, the pathophysiological mechanisms of spot sign remained undefined with a series of possible explanations including breakdown of blood–brain barrier, microaneurysms, and pseudoaneurysms.\textsuperscript{[9]} Studies on spot sign differed in terms of population, imaging technique, onset-to-scan time, and definition of outcomes, resulting in a wide range of frequencies and predictive values across studies. Thus, we performed this meta-analysis to evaluate the predictive ability of spot sign for HE or poor outcome and try to define the factors that influence the accuracy.
2. Methods

2.1. Literature search and selection criteria

We performed this study following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. All analyses were based on previous published studies, thus no ethical approval and patient consent was required. We systematically searched PubMed, Embase, and the Cochrane Library between January 1995 and July 2017. ICH, spot sign (contrast extravasation), CTA, and their synonyms were the search terms. The language was restricted to English. Reference lists of the identified articles were also examined to identify studies that might be missed by database search. HE was defined as an increase in hematoma volume of >6 mL or >30% from the baseline volume.[6,8] The primary outcome measurement of this analysis was HE and the secondary outcome measurements included death and poor clinical outcome measured by the modified Rankin Scale (mRS).

Two authors (XX and JZ) identified potentially relevant studies independently, resolving any disagreement or uncertainty by discussion. The final list of included studies was decided on consensus. Studies were included if they met the following inclusion criteria: original articles investigating CTA spot sign in patients with spontaneous ICH (involving at least 20 cases); reported clear definition of HE which was in line with our standard; reporting or allowing calculation of prevalence, sensitivity, and specificity of spot sign in predicting HE, death, or poor outcome. Studies reporting patients with secondary ICH and case reports were excluded.

2.2. Data extraction and quality assessment

Two investigators (XX and JZ) independently reviewed the full text of selected studies and extracted necessary information using a standardized form. The following information was abstracted: author, design, study period, effective sample size, computed tomography (CT) modality, onset to CTA scan time, definition of HE, time from CTA scan to HE assessment, blindness, and outcome measurements (death or poor outcome defined as mRS ≥ 3). Quality assessment for each study was by the QUADAS-2 tool and disagreements were resolved by discussion and consensus.

2.3. Statistical analysis

Data were pooled in a meta-analysis when at least three studies with relevant data were available. Results were combined using a
| Author      | Study design | Country, period | Sample size | Male, % | Definition of HE | Time to CTA, h | CT modality | Time to HE assess, h | Blindness | Prognosis measurement                          |
|-------------|--------------|----------------|-------------|---------|-----------------|---------------|-------------|----------------------|-----------|-----------------------------------------------|
| Wada        | P            | USA, 2004–2006 | 39          | 67      | >6mL or >30%    | >3            | CTA         | <48                  | NA        | In-hos mort                                  |
| Goldstein   | R            | USA, 2002–2006 | 104         | 53      | >33%            | >48           | CTA         | <48                  | Yes       | In-hos mort                                  |
| Delgado     | R            | USA, 2000–2008 | 367         | 58      | >6mL or >30%    | Mean: 7.4     | CTA; POCT   | <24                  | Yes       | NA                                            |
| Edelies     | R            | Canada, 2004–2008 | 61         | 67      | >6mL or >30%    | <6            | CTA; POCT   | <24                  | Yes       | NA                                            |
| Delgado*    | R            | USA, 2000–2008 | 573         | 54      | >6mL or >30%    | Mean: 7.4     | CTA         | <48                  | Yes       | In-hos mort, 3-mo PO                        |
| Park        | P            | Korea, 2007–2009 | 110        | 63      | >6mL or >30%    | <24           | CTA         | <24                  | NA        | 3-mo mort                                    |
| Rodriguez-Luna | P      | Spain, 2009–2010 | 89          | 58      | >6mL or >33%    | <6            | CTA         | <24                  | Yes       | NA                                            |
| Li          | P            | China, 2007–2010 | 139        | 68      | >12.5 mL or >30%| <6            | CTA         | <24                  | Yes       | In-hos mort/PO, 3-mo mort/PO                 |
| Wang        | R            | China, 2007–2010 | 312        | 57      | >6mL or >33%    | <3            | CTA         | <24                  | NA        | NA                                            |
| Demchuk*    | P            | Multicenter, 2006–2010 | 228      | 57      | >6mL or >33%    | <6            | CTA         | <24                  | Yes       | 3-mo mort                                    |
| Remero      | P            | USA, 2009–2010 | 131         | 61      | >6mL or >33%    | <24           | CTA         | <24                  | NA        | In-hos mort                                  |
| Sun         | P            | China, 2009–2010 | 112         | 64      | >6mL or >30%    | <6            | CTA; CTP    | <24                  | Yes       | NA                                            |
| Curra       | P            | USA, 2012–2013 | 74          | 55      | >6mL or >33%    | <24           | CTA         | <24                  | Yes       | In-hos mort                                  |
| Han         | R            | Korea, 2008–2012 | 187         | 50      | >12.5 mL or >30%| <24           | CTA         | <24                  | NA        | In-hos mort                                  |
| Hotta       | R            | Japan, 2009–2012 | 198         | 58      | >12.5 mL or >30%| <24           | CTA         | <24                  | NA        | In-hos mort                                  |
| Moon        | R            | Korea, 2005–2012 | 287         | 56      | >6mL or >33%    | <12           | CTA         | <24                  | NA        | 1-mo mort                                    |
| Ovesen      | P            | Denmark, 2011–2012 | 21         | 72      | 12.5 mL        | <4.5          | CTA         | <24                  | NA        | NA                                            |
| Rodriguez-Luna | P      | Multicenter, 2006–2012 | 320      | NA      | >6mL or >33%    | <6            | CTA; first and delayed | <24 | Yes | Neurological deterioration                   |
| Tsukabe     | R            | Japan, 2009–2014 | 83          | 63      | >6mL or >30%    | <6            | CTA; first and delayed | <24 | Yes | NA                                            |
| Brouwers    | P            | USA, 1994–2011 | 817         | 56      | >6mL or >33%    | Med: 5        | CTA; first and delayed | Med: 18 | Yes | NA                                            |
| Hou         | R            | China, 2012–2013 | 53          | 64      | >33%            | <6            | CTA         | <24                  | NA        | NA                                            |
| Kim         | R            | Korea, 2009–2011 | 316         | NA      | >6mL or >33%    | <24           | CTA         | <24                  | NA        | NA                                            |
| Boulouis    | P            | USA, 2012–2013 | 222*        | 53      | >6mL or >33%    | Med: 3.2      | CTA         | <48                  | Yes       | NA                                            |
| Morotti     | R            | USA, 2001–2015 | 709         | 56      | >6mL or >30%    | <48           | CTA         | <48                  | Yes       | NA                                            |
| Morotti*    | R            | USA, 2001–2015 | 49          | 55      | >6mL or >30%    | <24           | CTA         | <48                  | Yes       | In-hos mort, 1-mo mort                       |
| Rodriguez-Luna* | P     | Multicenter, 2006–2012 | 189      | 56      | >6mL or >33%    | <6            | CTA         | <24                  | Yes       | 3-mo mort/PO                                 |
| Wang        | P            | China, 2014–2015 | 72          | 75      | ≥6mL or ≥33%    | <6            | CTP         | <24                  | Yes       | 3-mo mort                                    |
| Nishiyama   | R            | Japan, 2013–2016 | 177         | 60      | ≥12.5 mL or ≥33%| <6            | CTA         | <48                  | NA        | In-hos mort                                  |
| Romero      | R            | USA, 2009–2012 | 123         | 61      | >6mL or >33%    | <24           | CTA         | <48                  | NA        | In-hos mort                                  |

CT = computed tomography, CTA = CT angiography, CTP = CT perfusion, HE = hematoma expansion, hos = hospital, Med = median, mo = month, mort = mortality, Multicenter = multicenter, NA = not available, P = prospective, POCT = postcontrast CT, PO = poor outcome (modified Rankin Scale ≥ 3), R = retrospective.

*Studies only included in the analyses of death and poor outcome.

†Multicenter including Canada, Germany, India, Poland, Spain, and USA.
random-effects model with DerSimonian–Laird approach. The positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR), as well as sensitivity and specificity were calculated. The strength of association between spot sign and HE, death, or poor outcome (mRS ≥ 3) were quantified by the odds ratio (OR) and their corresponding 95% confidence interval (CI), using the inverse-variance weighting method for aggregation. Heterogeneity between studies was assessed by Q test and $I^2$ statistics. For qualitative interpretation of heterogeneity, $I^2$ values of at least 50% were considered to represent moderate degree of heterogeneity, while $I^2$ values of at least 75% indicated high heterogeneity. Summary receiver operating characteristic (SROC) curves were constructed and area under the curve (AUC) was calculated. Publication bias was evaluated both graphically using a funnel plot and with the Egger statistical test. Subgroup analyses were conducted to explore the possible origin of heterogeneity. A $P$ value of <.1 indicated heterogeneity or publication bias. Meta-analyses were conducted using the Stata/MP 14.1 (Stata Corp, TX).

3. Results

3.1. Characteristics of included studies

Systematic search of PubMed, the Cochrane Library, and Embase yielded 146, 81, and 15 results, respectively. After removing duplicates, we identified 64 relevant original studies by screening the titles and abstracts. Thirty-one studies were further excluded, including 14 studies with no detailed records of HE or outcome, 5 studies of nonspontaneous ICH, four review articles, 5 case reports, and three studies used HE definitions contradictory to our criteria. Four studies conforming with the inclusion criteria were also excluded since they reported the same cohorts as other studies and only studies with the largest sample size and detailed information were included in our analysis.[10–13] Finally, 29 studies were included in this meta-analysis (Fig. 1). Characteristics of included studies, methodological key issues, and quality indicators were summarized in Table 1. Among all the studies, four were only included in the analysis of death or poor outcome since these data on HE had been incorporated in other studies.[14–17] Finally, 25 studies containing 5514 patients were pooled in to analyze the sensitivity and specificity of CTA spot sign in predicting HE,[4,7–9,18–38] 10 studies were pooled in to analyze risk of in-hospital death in ICH patients with CTA spot sign,[4,8,9,21,23,25–27,37,38] six studies for analysis of risk of 3-month death,[15,16,19–21,36] three studies for risk of poor outcome at discharge,[21,25,26] and four studies for analysis of risk of 3-month poor outcome.[14,16,21,23] From inspection of each included study, spot sign positive group and spot sign negative group were the same in basic characteristics (age, gender, or stroke severity).

3.2. Spot sign and prediction for HE

The crude prevalence of spot sign on CTA was 23.4% (95% CI 19.9–26.9) in patients with spontaneous ICH. The random-effects model with DerSimonian–Laird approach. The positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR), as well as sensitivity and specificity were calculated. The strength of association between spot sign and HE, death, or poor outcome (mRS ≥ 3) were quantified by the odds ratio (OR) and their corresponding 95% confidence interval (CI), using the inverse-variance weighting method for aggregation. Heterogeneity between studies was assessed by Q test and $I^2$ statistics. For qualitative interpretation of heterogeneity, $I^2$ values of at least 50% were considered to represent moderate degree of heterogeneity, while $I^2$ values of at least 75% indicated high heterogeneity. Summary receiver operating characteristic (SROC) curves were constructed and area under the curve (AUC) was calculated. Publication bias was evaluated both graphically using a funnel plot and with the Egger statistical test. Subgroup analyses were conducted to explore the possible origin of heterogeneity. A $P$ value of <.1 indicated heterogeneity or publication bias. Meta-analyses were conducted using the Stata/MP 14.1 (Stata Corp, TX).
pooled incidence of HE was 21.2% (95% CI 18.6–23.7): 57.5% (95% CI 50.9–64.0) among patients with spot sign versus 10.6% (95% CI 8.4–12.8) in patients without. There was significant correlation of spot sign with increased risk of HE (pooled OR 8.49, 95% CI 7.28–9.90; \( P < 0.001, I^2 = 75.8\% \)). Spot sign yielded a combined sensitivity of 62% (95% CI 54–69) and a specificity of 88% (95% CI 85–91) for predicting HE (Fig. 2). The combined PLR was 5.2 (95% CI 4.1–6.5), the summary NLR was 0.43 (95% CI 0.35–0.53), and the DOR was 12 (95% CI 8–17).

The SROC curve produced an AUC of 0.86 (Fig. 3), which meant that spot sign had a fine prediction ability for HE. The Q test demonstrated significant heterogeneity (\( P < 0.01 \)) and visual inspection of the funnel plot and the Deeks test (\( P = 0.03 \)) revealed publication bias. We further performed subgroup analyses in the light of study design, blind assessment, sample size, and publication year (Table 2). Studies with a sample size no more than 130 and studies published in 2012 or earlier tended to produce higher sensitivity while specificity was easily influenced by all the stratifications (Fig. 4).

3.3. Spot sign and clinical outcomes

In the analysis of in-hospital mortality, 10 studies containing 1900 patients were included. The pooled in-hospital mortality rate was 41.3% (95% CI 29.5–53.1) in patients with spot sign versus 12.8% (95% CI 7.9–17.7) in patients free of spot sign (\( P < 0.01 \)). Risk of in-hospital death was much higher in patients with evidence of spot sign, when compared with patients without

![SROC with Prediction & Confidence Contours](image)

Figure 3. Summary receiver operating characteristic curve of spot sign for predicting hematoma expansion. The regression line summarizes the overall predictive accuracy. AUC = area under the curve.

| Parameter       | Category | Studies | Sensitivity   | \( P_1 \) | Specificity | \( P_2 \) |
|-----------------|----------|---------|---------------|----------|-------------|----------|
| Pro design      | Yes      | 12      | 0.59 [0.47–0.71] | 0.21     | 0.67 [0.82–0.92] | 0.00     |
|                 | No       | 13      | 0.64 [0.53–0.75] | —        | 0.88 [0.84–0.92] | —        |
| Blindness       | Yes      | 13      | 0.59 [0.48–0.70] | 0.16     | 0.86 [0.82–0.90] | 0.00     |
|                 | No       | 12      | 0.65 [0.53–0.76] | —        | 0.89 [0.85–0.92] | —        |
| Sample size     | > 130    | 13      | 0.56 [0.45–0.68] | 0.03     | 0.69 [0.86–0.92] | 0.00     |
|                 | \( \leq 130 \) | 12      | 0.69 [0.58–0.80] | —        | 0.86 [0.81–0.91] | —        |
| Pub year        | > 2012   | 18      | 0.56 [0.47–0.65] | 0.01     | 0.88 [0.85–0.91] | 0.00     |
|                 | \( \leq 2012 \) | 7       | 0.75 [0.63–0.87] | —        | 0.87 [0.81–0.93] | —        |

CTA = computed tomography angiography. Pro design = prospective design. Pub year = study publication year.
(pooled OR 5.08, 95% CI 3.16–8.18; $I^2 = 65.0\%$) (Fig. 5A). For the evaluation of 3-month mortality, we were able to include six studies containing 810 patients. Similarly, the risk of 3-month death in patients with spot sign was 3.8 times that of patients without spot sign (pooled OR 3.80, 95% CI 2.62–5.52; $I^2 = 0.0\%$) (Fig. 5B). No obvious publication bias in the analysis of mortality was uncovered by examination of the funnel plot.

Three studies including 444 patients and 4 studies containing 857 patients were pooled in the analyses of in-hospital and 3-month poor outcome, respectively. At discharge, 89.9% (95% CI 84.3–95.6) patients with spot sign got a poor outcome (mRS ≥ 3) while 59.3% (95% CI 35.9–82.7) patients without spot sign got a poor outcome ($P < .01$). Spot sign was a risk factor of poor outcome at discharge (pooled OR 6.40, 95% CI 3.41–12.03; $I^2 = 0.0\%$) (Fig. 5C). At 3-month follow-up, the percentage of poor outcome was 68.2% (95% CI 45.0–91.5) in patients with spot sign versus 34.3% (95% CI 21.8–46.9) in patients without ($P < .01$). The risk of poor outcome at 3-month follow-up was much higher in patients with spot sign (pooled OR 4.44, 95% CI 2.33–8.46; $I^2 = 56.5\%$) (Fig. 5D).

4. Discussion

It has been well acknowledged that the initial hemorrhage volume is not static but frequent progresses due to continued bleeding and rebleeding, generally within the early hours after ictus.\textsuperscript{[39]} HE is shown to occur in up to 38% patients, most commonly in the first 6 hours after symptom onset.\textsuperscript{[40]} HE is an independent predictor of mortality and diminished functional outcome, while CTA spot sign is a recently validated predictor of HE in patients with spontaneous ICH.\textsuperscript{[8]} The relationship between spot sign and HE has been reviewed,\textsuperscript{[41,42]} however, only limited studies were included in that study. The association between number of spot sign and mortality or poor outcome had never been quantitative assessed. More comprehensive and updated studies reporting both HE data and clinical outcome data were incorporated in our study.
Since most studies included did not perform a delayed phase CTA, data in the meta-analysis were spot sign on first-pass CTA when applicable. Our results demonstrated that CTA spot sign had a moderate sensitivity (62%) and a high specificity (88%) for predicting HE. Interestingly, four studies investigating both first-pass and delayed CTA showed that the frequency of spot sign in the delayed CTA acquisitions was higher than in the first-pass CTA.[4,25,30,31] Further analysis of delayed CTA spot sign showed a much higher sensitivity (79%) and a slightly lower specificity (84%) for predicting HE. Study by Sun et al showed that the combination of CT perfusion could also improve the accuracy of spot sign in prediction of HE.[24] Ederies et al reported that combination of postcontrast CT leakage with CTA spot sign increased the sensitivity from 78% to 94%.[18] Nevertheless, the results were based on only four studies and more investigations are needed to verify this finding. The explanation for above changes might be that spot sign is a dynamic process and delayed imaging may help explore it with increased time interval during which the contrast can circulate and infiltrate into the region of hematoma. Combination of CTA with other different CT modalities add to the accuracy for predicting HE; however, adding a CT modality is expected to increase the radiation dose and the risk–benefit ratio should be carefully judged and weighed before widespread application.

Spot sign is a strong predictor of poor outcome (mRS ≥ 3) and increased mortality risk both at discharge and at 3-month follow-up. According to previous research findings, major predictors of increased early mortality and adverse outcome during the acute phase of ICH are HE, intraventricular hemorrhage with obstructive hydrocephalus, and hyperglycemia. Spot sign is usually associated with larger hemorrhage volume, a more severe clinical presentation, and has a quite high accuracy in predicting HE. These reasons may partially explain the association between spot sign and clinical outcomes. The sensitivity and specificity of spot sign for predicting clinical outcomes was summarized in Table 3. Since only 3 studies reported the rate of poor outcome at discharge, this sensitivity and specificity was incomputable. On the whole, the accuracy of spot sign for predicting clinical outcomes.

### Table 3

Accuracy of spot sign for predicting clinical outcomes.

| Clinical outcomes   | Study, n | Sensitivity (95% CI) | Specificity (95% CI) | PLR (95% CI) | NLR (95% CI) | DOR (95% CI) | AUC (95% CI) |
|---------------------|----------|----------------------|----------------------|--------------|--------------|--------------|--------------|
| In-hos mortality    | 10       | 53% (43–64)          | 81% (74–87)          | 2.9 (2.1–4.0) | 0.57 (0.46–0.71) | 5 (3–8)      | 0.74 (0.70–0.77) |
| 3-mo mortality      | 6        | 49% (38–59)          | 80% (74–85)          | 2.4 (1.9–3.1) | 0.64 (0.53–0.77) | 4 (3–5)      | 0.71 (0.67–0.75) |
| 3-mo poor outcome   | 4        | 34% (26–43)          | 89% (82–93)          | 3.1 (1.9–5.0) | 0.74 (0.65–0.84) | 4 (2–7)      | 0.69 (0.65–0.73) |

3-mo = 3-month, AUC = area under curve, CI = confidence interval, dis = discharge, DOR = diagnostic odds ratio, in-hos = in-hospital, NLR = negative likelihood ratio, PLR = positive likelihood ratio.
outcomes was much lower than that for predicting HE. The definition of clinical outcome varied across studies and the variety in clinical outcomes was susceptible to outcome reporting bias.

While the mechanisms of HE are still not well understood, both primary and secondary vessel injury hypotheses have been proposed. It is important to note that the presence of the dynamic spot sign within hematoma may reflect ongoing bleeding, and most of the spot signs occurred in the arterial phase, suggesting small artery damage and bleeding. The success of emergent and future interventions aimed at preventing HE and subsequent poor outcome, including hemostatic drugs, will likely depend on the accurate selection of patients at risk of HE and poor outcome.[23,26]

There are several limitations that should be acknowledged in this study. First of all, time from onset to CTA examination and patient’s baseline ICH volume varied across studies. Caution should be taken that there was obvious publication bias and heterogeneity between studies for HE prediction. Besides, the number of studies reporting spot sign and clinical outcome was limited with small sample size. A large proportion of studies were retrospective and unblinded, adding to the risk of selection bias. Finally, the timing of scan, scanner type, scanning parameters, and injection method of contrast might also be confounding factors which were generally unclear and variable across studies.

5. Conclusions

In conclusion, the overall incidence of CTA spot sign after spontaneous ICH was substantial. Our study demonstrated that the CTA spot sign appeared to be a strong risk factor of death and poor clinical outcome as well as a potential imaging biomarker of HE in patients with spontaneous ICH. Further standardized studies are needed to better investigate the mechanism of HE and the association between spot sign and clinical outcome.

Author contributions

Conceptualization: Xiaolei Chen.

Data curation: Xinghua Xu, Jiashu Zhang, Kai Yang, Qun Wang.

Formal analysis: Xinghua Xu, Kai Yang.

Funding acquisition: Xiaolei Chen.

Methodology: Xinghua Xu, Jiashu Zhang, Kai Yang, Bainaan Xu.

Resources: Bainan Xu, Xiaolei Chen.

Software: Xinghua Xu, Jiashu Zhang, Qun Wang.

Supervision: Xiaolei Chen.

Visualization: Jiashu Zhang.

Writing – original draft: Xinghua Xu, Kai Yang.

Writing – review and editing: Xinghua Xu, Jiashu Zhang, Kai Yang, Qun Wang, Bainan Xu, Xiaolei Chen.

References

[1] van Asch CJ, Luijte MJ, Rinkel GJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010;9:167–76.

[2] Flaherty ML, Haverbusch M, Sekar P, et al. Long-term mortality after intracerebral hemorrhage. Neurology 2006;66:1182–6.

[3] Davis SM, Broderick J, Hemmerci M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006;66:1175–81.

[4] Delgado Almendoz JE, Yoo AJ, Stone MJ, et al. Dynamic spot sign in primary intracerebral hemorrhage identifies patients at highest risk for hematoma expansion: the spot sign score. Stroke 2009;40:2994–3000.

[5] Brouwers HB, Greenberg SM. Hematoma expansion following acute intracerebral hemorrhage. Cerebrovasc Dis 2013;35:195–201.

[6] Broderick JP, Diringer MN, Hill MD, et al. Determinants of intracerebral hemorrhage growth: an exploratory analysis. Stroke 2007;38:1072–5.

[7] Boulouis G, Morotti A, Brouwers HB, et al. Association between hypodensities detected by computed tomography and hematoma expansion in patients with intracerebral hemorrhage. JAMA Neurol 2016;73:961–8.

[8] Wada R, Aviv RI, Fox AJ, et al. CT angiography “spot sign” predicts hematoma expansion in acute intracerebral hemorrhage. Stroke 2007;38:1257–62.

[9] Goldstein JN, Fazen LE, Snider R, et al. Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage. Neurology 2007;68:889–94.

[10] Brouwers HB, Falcone GJ, McNamara KA, et al. CTA spot sign predicts hematoma expansion in patients with delayed presentation after intracerebral hemorrhage. Neurocrit Care 2012;17:421–8.

[11] Rodriguez-Luna D, Pimerio S, Rubiera M, et al. Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage. Eur J Neurol 2015;20:1277–83.

[12] Huynh TJ, Demchuk AM, Dowlatshahi D, et al. Spot sign number is the most important spot sign characteristic for predicting hematoma expansion using first-pass computed tomography angiography: analysis from the predict study. Stroke 2013;44:972–7.

[13] Blacquiere D, Demchuk AM, Al-Hazzaa M, et al. Intracerebral hematoma morphologic appearance on noncontrast computed tomography predicts significant hematoma expansion. Stroke 2015;46:3111–6.

[14] Delgado Almendoz JE, Yoo AJ, Stone MJ, et al. The spot sign score in primary intracerebral hemorrhage identifies patients with highest risk of in-hospital mortality and poor outcome among survivors. Stroke 2010;41:54–60.

[15] Demchuk AM, Dowlatshahi D, Rodriguez-Luna D, et al. Prediction of hematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol 2012;11:307–14.

[16] Rodriguez-Luna D, Coscojuela P, Rubiera M, et al. Ultraearly hematoma growth in active intracerebral hemorrhage. Neurology 2016;87:337–44.

[17] Morotti A, Jessell MJ, Brouwers HB, et al. CT angiography spot sign, hematoma expansion, and outcome in primary pontine intracerebral hemorrhage. Neurocrit Care 2016;25:79–85.

[18] Edentes A, Demchuk A, Chia T, et al. Postcontrast CT extravasation is associated with hematoma expansion in CTA spot negative patients. Stroke 2009;40:1672–6.

[19] Park SY, Kong MH, Kim JH, et al. Role of “spot sign” on CT angiography to predict hematoma expansion in spontaneous intracerebral hemorrhage. J Korean Neurosurg Soc 2010;48:399–405.

[20] Rodríguez-Luna D, Rubiera M, Ribo M, et al. Ultraearly hematoma growth predicts poor outcome after acute intracerebral hemorrhage. Neurology 2011;77:1599–604.

[21] Li N, Wang Y, Wang W, et al. Contrast extravasation on computed tomography angiography predicts clinical outcome in primary intracerebral hemorrhage: a prospective study of 139 cases. Stroke 2011;42:3441–6.

[22] Wang YH, Fan JY, Luo GD, et al. Hematoma volume affects the accuracy of computed tomographic angiography “spot sign” in predicting hematoma expansion after acute intracerebral hemorrhage. Eur Neurol 2011;65:150–5.

[23] Remero JM, Brouwers HB, Lu J, et al. Prospective validation of the computed tomographic angiography spot sign score for intracerebral hemorrhage. Stroke 2013;44:3907–12.

[24] Sun SJ, Gao PY, Sui BB, et al. “Dynamic spot sign” on CT perfusion source images predicts haematoma expansion in acute intracerebral haemorrhage. Eur Radiol 2013;23:1846–54.

[25] Ciura VA, Brouwers HB, Pizzolato R, et al. Spot sign on 90-second delayed computed tomography angiography improves sensitivity for hematoma expansion and mortality: prospective study. Stroke 2014;45:3293–7.

[26] Han JH, Lee JM, Koh EJ, et al. The spot sign predicts hematoma expansion, outcome, and mortality in patients with primary intracerebral hemorrhage. J Korean Neurosurg Soc 2014;56:303–9.
[29] Ovesen C, Christensen AF, Krieger DW, et al. Time course of early postadmission hematoma expansion in spontaneous intracerebral hemorrhage. Stroke 2014;45:994–9.

[30] Rodriguez-Luna D, Dowlatshahi D, Aviv RI, et al. Venous phase of computed tomography angiography increases spot sign detection, but intracerebral hemorrhage expansion is greater in spot signs detected in arterial phase. Stroke 2014;45:734–9.

[31] Tsukabe A, Watanabe Y, Tanaka H, et al. Prevalence and diagnostic performance of computed tomography angiography spot sign for intracerebral hematoma expansion depend on scan timing. Neuroradiology 2014;56:1039–45.

[32] Brouwers HB, Chang Y, Falcone GJ, et al. Predicting hematoma expansion after primary intracerebral hemorrhage. JAMA Neurol 2014;71:138–64.

[33] Hou XY, Gao PY. Perihematomal perfusion typing and spot sign of acute intracerebral hemorrhage with multimode computed tomography: a preliminary study. Chin Med Sci J 2014;29:139–43.

[34] Kim SH, Jung HH, Whang K, et al. Which emphasizing factors are most predictive of hematoma expansion in spot sign positive intracerebral hemorrhage? J Korean Neurosurg Soc 2014;56:86–90.

[35] Morotti A, Romero JM, Jessel MJ, et al. Effect of CTA tube current on spot sign detection and accuracy for prediction of intracerebral hemorrhage expansion. AJNR Am J Neuroradiol 2016;37:1781–6.

[36] Wang B, Yan S, Xu M, et al. Timing of occurrence is the most important characteristic of spot sign. Stroke 2016;47:1233–8.

[37] Nishiyama J, Sorimachi T, Aoki R, et al. Occurrence of spot signs from hypodensity areas on precontrast ct in intracerebral hemorrhage. Neuroradiology 2017;69:1-6.

[38] Romero JM, Hito R, Dejam A, et al. Negative spot sign in primary intracerebral hemorrhage: potential impact in reducing imaging. Emerg Radiol 2017;24:1–6.

[39] Qureshi AI, Tuhrim S, Broderick JP, et al. Spontaneous intracerebral hemorrhage. N Engl J Med 2001;344:1450–60.

[40] Kazui S, Naritomi H, Yamamoto H, et al. Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke 1996;27:1783–7.

[41] Du FZ, Jiang R, Gu M, et al. The accuracy of spot sign in predicting hematoma expansion after intracerebral hemorrhage: a systematic review and meta-analysis. PLoS ONE 2014;9:e115777.

[42] Del Giudice A, D’Amico D, Sobesky J, et al. Accuracy of the spot sign on computed tomography angiography as a predictor of haematoma enlargement after acute spontaneous intracerebral haemorrhage: a systematic review. Cerebrovasc Dis 2014;37:268–76.

[43] Mayer SA, Brun NG, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777–85.